T 0070907

Pricing Availability   Qty
Cat.No. 2301 - T 0070907 | C12H8N3O3Cl | CAS No. 313516-66-4
Description: Highly potent and selective covalent PPARγ antagonist
Chemical Name: 2-Chloro-5-nitro-N-4-pyridinylbenzamide
Purity: ≥99% (HPLC)
Datasheet
Citations (4)
Reviews
Literature

Biological Activity

Potent and selective irreversible PPARγ antagonist (IC50 = 1 nM). Displays > 800-fold selectivity for PPARγ over PPARα and PPARδ. Blocks transcriptional activity of PPARγ in vitro and inhibits rosiglitazone-induced adipogenesis.

Compound Libraries

T 0070907 is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 277.67
Formula C12H8N3O3Cl
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 313516-66-4
PubChem ID 2777391
InChI Key FRPJSHKMZHWJBE-UHFFFAOYSA-N
Smiles [O-][N+](=O)C1=CC=C(Cl)C(=C1)C(=O)NC1=CC=NC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 27.8 100
1eq. HCl 27.77 100

Preparing Stock Solutions

The following data is based on the product molecular weight 277.67. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.6 mL 18.01 mL 36.01 mL
5 mM 0.72 mL 3.6 mL 7.2 mL
10 mM 0.36 mL 1.8 mL 3.6 mL
50 mM 0.07 mL 0.36 mL 0.72 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References

References are publications that support the biological activity of the product.

Lee et al (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities. J.Biol.Chem. 277 19649 PMID: 11877444

Rockwell and Kaminski (2004) A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J.Pharmacol.Exp.Ther. 311 683 PMID: 15284281

Schaefer et al (2005) Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 65 2251 PMID: 15781638


If you know of a relevant reference for T 0070907, please let us know.

View Related Products by Target

View Related Products by Product Action

View all PPARγ Antagonists

Keywords: T 0070907, T 0070907 supplier, potent, selective, PPARγ, PPARgamma, antagonists, Peroxisome, Proliferator-activating, Receptors, T0070907, 2301, Tocris Bioscience

4 Citations for T 0070907

Citations are publications that use Tocris products. Selected citations for T 0070907 include:

Bullers et al (2014) The human tissue-biomaterial interface: a role for PPARγ-dependent glucocorticoid receptor activation in regulating the CD163+ M2 macrophage phenotype. Tissue Eng Part A 20 2390 PMID: 24548290

Kassotis et al (2017) Characterization of Adipogenic Chemicals in Three Different Cell Culture Systems: Implications for Reproducibility Based on Cell Source and Handling. Sci Rep 7 42104 PMID: 28176856

Hamtiaux et al (2012) The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer 12 92 PMID: 22429826

Hamtiaux et al (2011) Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PLoS One 6 e26823 PMID: 22046372


Do you know of a great paper that uses T 0070907 from Tocris? Please let us know.

Reviews for T 0070907

There are currently no reviews for this product. Be the first to review T 0070907 and earn rewards!

Have you used T 0070907?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Nuclear Receptors

Nuclear Receptors Product Listing

A collection of over 150 products for key nuclear receptors, the listing includes research tools for the study of:

  • Androgen Receptors
  • Estrogen Receptors
  • Retinoic Acid Receptors
  • Retinoid X Receptors
  • Vitamin D Receptors
Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.